Targets › TCRB
3 programs from 3 companies in 5 trials: 3 Phase 2, 2 Phase 1; Hematology, Metabolic and endocrine, Oncology; next expected readout Jan 2027.
Open in Phaseline: the race on TCRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) Selective depletion of T cells expressing TCR alpha/beta to reduce graft-versus-host disea | TCRA, TCRB | Phase 2 | Fanconi Anemia | Jan 2027 |
| Johns Hopkins All Children's Hospital | TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan | TCRA, TCRB, CD19 | Phase 2 | Hemoglobinopathy (Disorder); Primary Immune Deficiency Disorders | Jun 2027 |
| Marengo Therapeutics | STAR0602 Selective TCR-targeting bifunctional antibody-fusion molecule | TCRA, TCRB | Phase 1 | Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid Tumors | Jan 2027 |
Hemoglobinopathy (Disorder) (1) Primary Immune Deficiency Disorders (1) Fanconi Anemia (1) Triple Negative Locally Advanced Non-resectable Breast Cancer (1) Advanced Solid Tumors (1)
other (1), mixed (1), small molecule (1)
Johns Hopkins All Children's Hospital (1) Masonic Cancer Center, University of Minnesota (1) Marengo Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.